US Bancorp DE Acquires 28,080 Shares of Elanco Animal Health Incorporated $ELAN

US Bancorp DE lifted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 188.4% in the second quarter, according to its most recent filing with the SEC. The firm owned 42,986 shares of the company’s stock after acquiring an additional 28,080 shares during the period. US Bancorp DE’s holdings in Elanco Animal Health were worth $614,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in ELAN. Nuveen LLC bought a new position in Elanco Animal Health during the 1st quarter valued at about $115,212,000. Dimensional Fund Advisors LP lifted its holdings in Elanco Animal Health by 14.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company’s stock valued at $214,875,000 after purchasing an additional 2,563,740 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after purchasing an additional 2,445,872 shares during the last quarter. ASR Vermogensbeheer N.V. bought a new position in Elanco Animal Health during the 1st quarter valued at about $23,744,000. Finally, DDD Partners LLC lifted its holdings in Elanco Animal Health by 202.7% during the 1st quarter. DDD Partners LLC now owns 1,492,992 shares of the company’s stock valued at $15,676,000 after purchasing an additional 999,716 shares during the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Trading Up 4.4%

Shares of NYSE ELAN opened at $21.42 on Monday. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $21.76. The company has a market cap of $10.64 billion, a PE ratio of 24.91, a P/E/G ratio of 3.93 and a beta of 1.65. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61. The company has a 50-day moving average of $18.90 and a two-hundred day moving average of $14.81.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.19 billion. During the same quarter in the previous year, the company earned $0.30 EPS. Elanco Animal Health’s revenue was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, equities analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Stifel Nicolaus lifted their price target on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Piper Sandler lifted their price target on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, August 11th. Leerink Partnrs raised shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 17th. UBS Group boosted their target price on shares of Elanco Animal Health from $18.00 to $19.00 and gave the stock a “buy” rating in a research note on Friday, August 8th. Finally, William Blair raised shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating in a research note on Thursday, June 26th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Elanco Animal Health has a consensus rating of “Moderate Buy” and a consensus target price of $19.14.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.